查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2009114

氣喘治療市場規模、佔有率、趨勢和預測：按藥物類別、產品類型、治療方法、給藥途徑和地區分類，2026-2034 年

Asthma Therapeutics Market Size, Share, Trends and Forecast by Drug Class, Product Type, Treatment Type, Route of Administration, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2025年全球氣喘治療市場規模為191.6億美元。展望未來，IMARC Group預測，該市場將以1.73%的複合年成長率從2026年成長至2034年，到2034年達到224.9億美元。目前，北美市場佔據主導地位，預計2025年將佔全球市場佔有率的47.3%。該地區擁有完善的醫療保健基礎設施、較高的呼吸系統疾病發病率以及健全的法規結構，這些優勢有利於先進氣喘治療方案的快速核准和推廣，從而鞏固了其在全球氣喘治療市場的佔有率。

全球氣喘治療市場受多種因素共同驅動：呼吸系統疾病負擔日益加重、慢性呼吸道管理意識不斷提高以及藥物輸送系統的快速發展。兒童和成人氣喘盛行率的不斷上升，推動了對有效且標靶治療方法的需求。生物製藥和單株抗體的廣泛應用，拓展了治療選擇，使中重度氣喘患者能夠獲得更個人化和精準的治療方案。此外，全球老年人口的成長（老年人患呼吸系統疾病的風險更高）也進一步促進了多個地區氣喘治療市場的成長。

由於多種因素，美國正崛起為氣喘治療市場的重要區域。美國是世界上氣喘盛行率最高的國家之一，相當一部分人口需要持續的治療管理。美國肺臟協會報告稱，美國有2,680萬成年人和450萬兒童患有氣喘，凸顯了對持續治療和疾病管理的廣泛需求。這種持續的需求推動了市場的活躍發展，包括處方藥、先進的給藥裝置和生物製藥。吸入型皮質類固醇和長效BETA2受體激動劑的廣泛應用反映了醫師對現有治療方案的信心。此外，美國完善的醫療保健體系，包括廣泛的保險覆蓋、活躍的醫生網路和患者支持項目，正在擴大氣喘治療的可及性。

氣喘治療市場趨勢：

生物製藥的應用日益廣泛

生物製藥的日益普及標誌著重症氣喘治療的變革性轉變，尤其適用於對傳統治療方法反應不佳的患者。這些治療方法對嗜酸性粒細胞或過敏性氣喘患者特別有益，使醫護人員能夠根據特定患者的疾病特徵提供更有針對性和個人化的干涉措施。 2025年12月，美國食品藥物管理局（FDA）核准了葛蘭素史克（GSK）開發的depemokimab（Exdensur）作為重症嗜酸性粒細胞氣喘的附加維持治療生物製藥。這是該類別中首個獲準的、每年兩次給藥的生物製藥。隨著皮下和靜脈注射途徑的增加，這些治療方法的應用範圍正從住院患者擴展到門診病人。

智慧吸入器技術的進步

智慧吸入器技術的快速普及正在從根本上改變全球不同患者群體的氣喘管理方式。這些數位化設備整合了電子感測器和連接功能，能夠監控用藥模式、追蹤吸入技巧，並將即時數據傳輸到行動平台上的相關應用程式。資訊來源顯示，使用智慧吸入器的患者的用藥依從率達到71.4%，而傳統治療組的依從率為59.9%，這顯示智慧吸入器技術能夠顯著提高氣喘治療的依從性。監管機構對數位健康工具的支持以及智慧設備報銷途徑的開發，正在推動氣喘治療市場的發展，因為該領域正在採用先進的、技術主導的護理模式，這些模式有望顯著提高患者的用藥依從性和長期呼吸系統健康狀況。

聯合治療的作用日益增強

聯合治療在氣喘管理中的作用日益增強，正在顯著改變全球臨床治療通訊協定。將不同藥理類別的藥物合併使用，例如吸入性糖皮質激素與長效BETA2受體激動劑或白三烯受體拮抗劑，可以產生單一藥物治療無法達到的協同效應。 2024年5月，世界衛生組織（WHO）報告稱，全球約有2.62億人患有氣喘，每年約有45.5萬人死於氣喘，凸顯了開發更有效的治療策略（包括聯合治療）的必要性。此外，持續進行的探索新型聯合治療的臨床研究以及全球市場保險報銷範圍的擴大，都為氣喘治療市場帶來了樂觀前景，推動著該行業朝著提供日益全面和循證的呼吸系統護理方向發展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球氣喘治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 抗發炎藥
  • 支氣管擴張劑
  • 聯合治療

第7章 市場區隔：依產品類型分類

  • 吸入器
    • 主要類型
      • 乾粉吸入器
      • 定量噴霧吸入器
      • 緩霧吸入器
  • 噴霧器
    • 主要類型
      • 氣動霧化器
      • 超音波霧化器
      • 網狀霧化器

第8章 市場區隔：依治療類型分類

  • 快速起效的藥物
  • 長期氣喘管理藥物

第9章 市場區隔：依給藥途徑

  • 吸入
  • 口服
  • 腸外

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AstraZeneca PLC
    • Abbott Laboratories
    • Amgen Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck Sharp & Dohme Corp.
    • Novartis International AG
    • Sunovion Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A2338

The global asthma therapeutics market size was valued at USD 19.16 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 22.49 Billion by 2034, exhibiting a CAGR of 1.73% from 2026-2034. North America currently dominates the market, holding a market share of 47.3% in 2025. The region benefits from an extensive healthcare infrastructure, high prevalence of respiratory disorders, and robust regulatory frameworks that facilitate the timely approval and adoption of advanced asthma therapeutic solutions, reinforcing the global asthma therapeutics market share.

The global asthma therapeutics market is driven by a confluence of rising respiratory disease burden, growing awareness of chronic airway management, and rapid advancements in drug delivery systems. An increasing global prevalence of asthma among both pediatric and adult populations has intensified the demand for effective and targeted treatment regimens. The widespread adoption of biologics and monoclonal antibodies has expanded the treatment landscape, enabling more personalized and precision-based therapeutic approaches for patients with moderate to severe asthma. The expanding geriatric population globally, which tends to exhibit higher susceptibility to respiratory ailments, is additionally supporting asthma therapeutics market growth across multiple geographies.

The United States has emerged as a major region in the asthma therapeutics market owing to many factors. The nation carries one of the highest burdens of asthma globally, with a substantial portion of its population requiring continuous therapeutic management. According to reports, the American Lung Association reported that 26.8 million adults and 4.5 million children are living with asthma, emphasizing the widespread need for consistent treatment and disease management. This persistent demand has fueled robust market activity encompassing prescription medications, advanced delivery devices, and biologics. The widespread acceptance of inhaled corticosteroids and long-acting beta-agonists reflects physician confidence in established therapeutic pathways. Additionally, well-developed healthcare systems characterized by widespread insurance coverage, active physician networks, and patient support programs are enabling broader access to asthma medications.

ASTHMA THERAPEUTICS MARKET TRENDS:

Rising Adoption of Biologic Therapies

The growing adoption of biologic therapies represents a transformative shift in the management of severe asthma, particularly for patients who do not respond adequately to conventional treatment approaches. These therapies are especially beneficial for patients with eosinophilic or allergic phenotypes of asthma, enabling healthcare providers to deliver more targeted and individualized interventions based on specific patient disease profiles. In December 2025, the U.S. Food and Drug Administration approved depemokimab (Exdensur), developed by GSK, as an add-on maintenance biologic therapy for severe eosinophilic asthma, becoming the first biologic in this category designed for twice-yearly dosing. The increased availability of subcutaneous and intravenous administration options has expanded the reach of these treatments across hospital and outpatient settings alike.

Advancements in Smart Inhaler Technology

The rapid proliferation of smart inhaler technologies is fundamentally redefining asthma management practices across diverse patient demographics worldwide. These digitally enabled devices integrate electronic sensors and connectivity features that monitor medication usage patterns, track inhalation technique, and transmit real-time data to companion applications on mobile platforms. As per sources, that digital inhaler users achieved 71.4% medication adherence compared with 59.9% in standard-care groups, demonstrating improved asthma treatment compliance through connected inhaler technologies. Regulatory support for digital health tools and evolving reimbursement pathways for connected devices is reinforcing the asthma therapeutics market outlook as the sector embraces advanced, technology-driven care models promising meaningful improvements in patient adherence and long-term respiratory health outcomes.

Expanding Role of Combination Therapies

The expanding role of combination therapies in asthma management is significantly reshaping treatment protocols across clinical settings worldwide. Combining agents from different pharmacological classes, such as inhaled corticosteroids with long-acting beta-agonists or leukotriene receptor antagonists, offers synergistic benefits that single-agent therapies often cannot achieve independently. In May 2024, the World Health Organization reported that asthma affected around 262 million people globally and caused approximately 455 000 deaths annually, emphasizing the need for more effective treatment strategies including combination therapies. Furthermore, ongoing clinical investigations examining additional combination options, together with expanding reimbursement support across global markets, continue to underpin the positive asthma therapeutics market forecast as the industry advances toward increasingly holistic and evidence-based respiratory care delivery.

ASTHMA THERAPEUTICS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

  • Anti-Inflammatory Drugs
  • Bronchodilators
  • Combination Therapies

Anti-inflammatory drugs hold 62.8% of the market share, representing the foundational therapeutic category in asthma management, encompassing inhaled corticosteroids, leukotriene modifiers, and newer biologic agents designed to suppress airway inflammation at its source. These medications function by targeting the underlying inflammatory mechanisms responsible for airway hyperresponsiveness, mucus hypersecretion, and progressive bronchoconstriction, delivering meaningful symptomatic relief and reducing the risk of acute exacerbations. Inhaled corticosteroids, which constitute the primary subcategory, are widely recommended as first-line treatment across international asthma management guidelines due to their well-established safety and efficacy profiles. The emergence of biologic agents within the anti-inflammatory drug class has further expanded therapeutic options for patients with difficult-to-control and severe asthma phenotypes, enabling more precise targeting of specific immune pathways. Rising physician adoption of phenotype-guided treatment strategies continues to accelerate prescriptions within this category. Broader awareness of evolving asthma therapeutics market trends is encouraging healthcare systems to increasingly prioritize preventive anti-inflammatory therapies over reactive management approaches worldwide.

Analysis by Product Type:

  • Inhalers
    • Dry Powder Inhalers
    • Metered Dose Inhalers
    • Soft Mist Inhalers
  • Nebulizers
    • Pneumatic Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers

Inhalers lead the market with a share of 68.5%, offering a direct-to-lung drug delivery mechanism that maximizes therapeutic efficacy while minimizing systemic side effects. The category encompasses a diverse range of device types, including dry powder inhalers, metered dose inhalers, and soft mist inhalers, each designed to accommodate varying patient preferences, inhalation capacities, and severity levels. Metered dose inhalers remain the most widely used device type globally, given their portability, ease of use, and broad compatibility with multiple drug formulations including corticosteroids, bronchodilators, and combination therapies. As per sources, Viatris and Kindeva Drug Delivery launched Breyna(TM), the first U.S. FDA-approved generic version of Symbicort, a budesonide-formoterol inhalation aerosol used for asthma and COPD treatment. Dry powder inhalers are gaining traction owing to their propellant-free design and growing alignment with environmental sustainability initiatives across the pharmaceutical sector. Soft mist inhalers offer additional advantages for patients with coordination difficulties by producing a slow-moving aerosol cloud that optimizes lung deposition.

Analysis by Treatment Type:

  • Quick-Relief Medications
  • Long-Term Asthma Control Medications

Long-term asthma control medications dominate the market, with a share of 58.5%, encompassing a broad spectrum of therapies designed to reduce airway inflammation, prevent bronchoconstriction, and minimize the frequency and severity of asthma exacerbations over an extended period. These medications, which include inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, and biologic agents, are prescribed as maintenance therapy for patients with persistent asthma. Their primary objective is to achieve and sustain asthma control, reducing the need for rescue medications and emergency interventions. Healthcare guidelines across major markets consistently recommend long-term control medications as the cornerstone of chronic asthma management, given their demonstrated ability to improve quality of life and reduce hospitalizations. The proliferation of biologics within this category has introduced highly targeted treatment options that address specific disease phenotypes, further strengthening clinical outcomes. Increased awareness of proactive disease management and the growing emphasis on personalized medicine are supporting sustained expansion of this treatment category globally.

Analysis by Route of Administration:

  • Inhalation
  • Oral
  • Parenteral

Inhalation represents the leading segment, with a market share of 72.5%, as a route of administration is firmly established as the preferred delivery mechanism for asthma therapeutics worldwide, primarily due to its ability to deliver drugs directly to the site of action within the airways with high precision and minimal systemic exposure. This targeted approach significantly reduces the risk of systemic adverse effects commonly associated with oral or parenteral routes while enabling rapid onset of therapeutic action, making it particularly suitable for both maintenance and rescue therapy. The availability of a wide variety of inhaled formulations, including corticosteroids, bronchodilators, and combination products, supports comprehensive disease management across all severity levels. Technological advances in inhaler design, such as the development of more patient-friendly devices with dose counters, breath-actuation features, and digital connectivity, have further reinforced the dominance of the inhalation route.

REGIONAL ANALYSIS:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 47.3% of the share, maintaining the leading position in the market. The regions commanding position in the asthma therapeutics landscape is underpinned by a well-established healthcare infrastructure, a high disease burden, and a sophisticated pharmaceutical ecosystem that facilitates rapid adoption of innovative therapies. The region is home to the world's largest and most advanced healthcare markets, supported by substantial public and private investment in respiratory medicine research and development. Favorable regulatory pathways managed by agencies such as the U.S. Food and Drug Administration have historically enabled timely market entry for new drug approvals, including biologics and novel inhaler technologies. Comprehensive health insurance coverage and reimbursement structures across the United States and Canada have further expanded patient access to a broad spectrum of asthma therapies. Growing awareness of disease management best practices, robust clinical trial activity, and a strong pipeline of investigational asthma therapies are collectively sustaining the region's leadership position within the global market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ASTHMA THERAPEUTICS MARKET ANALYSIS

The region has the largest national market in terms of the total market size in the global asthma therapeutics industry. This is attributed to the exceptionally high prevalence rates of the disease in the country. Additionally, the country has an entrenched tradition of pharmaceutical innovation and healthcare accessibility. It has an extensive healthcare system that includes well-organized networks of physicians, pulmonologists, and well-funded research activities that ensure continuous innovation in the detection and treatment of the disease. Government agencies like the national institutes of health and the centers for disease control and prevention actively monitor the epidemiology of the disease. They fund research activities that seek to improve treatment outcomes. The adoption of guidelines by organizations like the National asthma education and prevention program has helped standardize treatment approaches. This ensures that patients receive consistent treatment, including the prescription of drugs, despite their demographics. The country has an entrenched system of health insurance that covers patients suffering from asthma. This has helped remove economic barriers to treatment. Organizations advocating for patients suffering from the disease, along with active public awareness campaigns, have helped improve patient recognition, early detection, and treatment adherence.

EUROPE ASTHMA THERAPEUTICS MARKET ANALYSIS

Europe represents a well-developed and strategically significant market for asthma therapeutics, characterized by high healthcare standards, universal insurance coverage in most member states, and strong governmental emphasis on respiratory health. The region exhibits a significant asthma burden across densely populated nations such as Germany, France, the United Kingdom, and Italy, where environmental factors including urbanization, air pollution, and allergen exposure contribute to persistently high prevalence rates. According to reports, the European Commission approved Tezspire (tezepelumab), developed by AstraZeneca, as an add-on maintenance treatment for patients aged 12 years and older with severe asthma inadequately controlled by high-dose inhaled corticosteroids and another therapy. The national health service model prevalent across many European nations supports universal access to asthma medications, reducing out-of-pocket costs for patients. Growing investment in digital health adoption, telemedicine infrastructure, and personalized medicine initiatives is advancing asthma management capabilities across the continent. Additionally, pan-European public health programs focused on early diagnosis, preventive care, and patient education are supporting better disease control and contributing to sustained demand for advanced asthma therapeutics.

ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET ANALYSIS

Asia-Pacific represents a rapidly growing market for asthma therapeutics, driven by a large population base, rising urbanization, and increasing prevalence of respiratory conditions across the region. Countries such as China, India, Japan, South Korea, and Australia are experiencing escalating asthma burdens attributable to worsening air quality, occupational exposures, and changing environmental conditions. Government-led healthcare expansion initiatives and increasing investment in pharmaceutical infrastructure are improving access to asthma medications in previously underserved areas. The growing middle class in emerging economies such as India and China is driving greater healthcare consumption, including increased utilization of branded and innovative asthma therapeutic products. Additionally, rising physician awareness of modern treatment protocols and expanding health insurance coverage are translating into improved diagnosis rates and stronger demand for effective, long-term asthma management solutions across both urban and rural populations.

LATIN AMERICA ASTHMA THERAPEUTICS MARKET ANALYSIS

Latin America presents a growing market for asthma therapeutics, supported by rising disease prevalence, improving healthcare access, and expanding pharmaceutical distribution networks. Brazil and Mexico serve as the primary market contributors in the region, driven by large patient populations, ongoing government healthcare investments, and strengthening insurance frameworks. Increasing urbanization and environmental degradation are elevating asthma incidence across the region. Regional health authorities are advancing public awareness campaigns to promote early diagnosis and consistent treatment adherence, further generating demand for therapeutic solutions. Nonetheless, affordability remains a key factor influencing treatment accessibility for a significant proportion of the Latin American patient population.

MIDDLE EAST AND AFRICA ASTHMA THERAPEUTICS MARKET ANALYSIS

The Middle East and Africa region represents an emerging market for asthma therapeutics, with demand driven by high disease prevalence rooted in environmental, climatic, and occupational risk factors across the region. Countries in the Gulf Cooperation Council, including Saudi Arabia and the United Arab Emirates, are making significant strides in healthcare infrastructure development and pharmaceutical market expansion. Increasing government investment in respiratory health programs and rising health awareness among the population are supporting market growth. However, limited healthcare access and affordability constraints in parts of sub-Saharan Africa continue to temper the overall pace of market development across the broader region.

COMPETITIVE LANDSCAPE:

The asthma therapeutics market is characterized by intense competitive activity among a select group of multinational pharmaceutical corporations that collectively dominate global drug development, manufacturing, and commercialization efforts. Market participants are actively engaged in advancing proprietary pipelines of biologic agents, inhaled corticosteroids, and novel combination therapies to address increasingly complex patient needs. Strategic collaborations, licensing agreements, and joint research initiatives are commonly employed to accelerate the progression of candidate molecules through clinical development phases. Companies are also investing substantially in device innovation, particularly in the development of smart inhalers and digitally enabled respiratory management platforms that align with evolving patient expectations and regulatory priorities.

The report provides a comprehensive analysis of the competitive landscape in the asthma therapeutics market with detailed profiles of all major companies, including:

  • AstraZeneca PLC
  • Abbott Laboratories
  • Amgen Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp.
  • Novartis International AG
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the asthma therapeutics market?

2. What is the future outlook of the asthma therapeutics market?

3. What are the key factors driving the asthma therapeutics market?

4. Which region accounts for the largest asthma therapeutics market share?

5. Which are the leading companies in the global asthma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Asthma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Anti-Inflammatory Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bronchodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Combination Therapies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Inhalers
    • 7.1.1 Market Trends
    • 7.1.2 Major Types
      • 7.1.2.1 Dry Powder Inhalers
      • 7.1.2.2 Metered Dose Inhalers
      • 7.1.2.3 Soft Mist Inhalers
    • 7.1.3 Market Forecast
  • 7.2 Nebulizers
    • 7.2.1 Market Trends
    • 7.2.2 Major Types
      • 7.2.2.1 Pneumatic Nebulizers
      • 7.2.2.2 Ultrasonic Nebulizers
      • 7.2.2.3 Mesh Nebulizers
    • 7.2.3 Market Forecast

8 Market Breakup by Treatment Type

  • 8.1 Quick-Relief Medications
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Long-Term Asthma Control Medications
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Inhalation
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Parenteral
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AstraZeneca PLC
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Abbott Laboratories
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Boehringer Ingelheim International GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 F. Hoffmann-La Roche Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck Sharp & Dohme Corp.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis International AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sunovion Pharmaceuticals Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 SWOT Analysis
    • 15.3.11 Teva Pharmaceutical Industries Ltd.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Asthma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Asthma Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Asthma Therapeutics Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Asthma Therapeutics Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Asthma Therapeutics Market: Breakup by Treatment Type (in %), 2025
  • Figure 6: Global: Asthma Therapeutics Market: Breakup by Route of Administration (in %), 2025
  • Figure 7: Global: Asthma Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Asthma Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Asthma Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Asthma Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Asthma Therapeutics (Combination Therapies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Asthma Therapeutics (Combination Therapies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Asthma Therapeutics (Inhalers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Asthma Therapeutics (Inhalers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Asthma Therapeutics (Nebulizers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Asthma Therapeutics (Nebulizers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Asthma Therapeutics (Quick-Relief Medications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Asthma Therapeutics (Quick-Relief Medications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Asthma Therapeutics (Inhalation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Asthma Therapeutics (Inhalation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Asthma Therapeutics (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Asthma Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Asthma Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Asthma Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia Pacific: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia Pacific: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Asthma Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Asthma Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Asthma Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Asthma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Asthma Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Asthma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Asthma Therapeutics Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 4: Global: Asthma Therapeutics Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 5: Global: Asthma Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 6: Global: Asthma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Asthma Therapeutics Market Structure
  • Table 8: Global: Asthma Therapeutics Market: Key Players